Abstract

A convergent synthesis of α-ketoamide inhibitors of Pin1 is described. An α-hydroxyorthothioester derivative of Ser was reacted directly with an amine synthon. The reaction was catalyzed by HgO and HgCl2 to form α-hydroxyamide. Thus, hydrolysis and coupling were combined in one step with 80% yield. Two diastereomers of a phospho-Ser-Pro α-ketoamide analogue were synthesized. The IC50 values of 100 μM and 200 μM were surprisingly weak for Pin1 peptidyl-prolyl isomerase.
α-Ketoamides have been widely used in developing inhibitors of peptidases,1 HDACs2,3 and peptidyl prolyl isomerases (PPIases).4 One of the best studied immunosuppressant drugs, FK506 has an α-ketoamide, and it is a transition state analogue inhibitor of FK506 binding proteins (FKBPs).5 α-Ketoamides have been used to inhibit several classes of proteases, such as serine proteases,6–10 cysteine proteases11–14 and HIV and FIV proteases.15
α-Ketoamides have an electron-deficient carbonyl due to the effect of the neighboring electron-withdrawing amide. α-Ketoamide containing inhibitors have been used to elucidate the mechanisms of enzymes, because they serve as transition state analogues to inhibit enzyme catalytic activity. This occurs for serine or cysteine proteases through the formation of a tetrahedral intermediate analogue (gem-diol or hemiketal) with the enzyme upon binding.16 FK506, a macrolide with an α-ketoamide functional group, has a dihedral angle of 95° to 100° between the two carbonyl groups.5 NMR studies of a 13C-labeled structure and a crystal structure of FK506 showed that the two carbonyls were orthogonal both in bound and unbound structures, indicating that FK506 acts as a “twisted amide” transition state analogue to inhibit FKBPs.5
Pin1, a PPIase enzyme belonging to the parvulin family, specifically recognizes pSer/pThr–Pro containing substrates, and regulates many cellular events such as cell cycle progression, transformation, and cell proliferation.17,18 Pin1 is overexpressed in many cancer cell lines, and plays an important role in oncogenesis.19,20 Pin1 is a potential diagnostic and therapeutic anti-cancer target.21–23 Thus, we are interested in developing potent and specific inhibitors of Pin1.24,25
Since α-ketoamides are an important class of enzyme inhibitors, numerous synthetic methods have been reported, including: cyano ylide coupling,26 transition-metal-catalysis,27 amidation of α-keto acids with amines,11,28 oxidation of α-hydroxyamides with Dess-Martin periodinane6 or TEMPO,29,30 and nucleophilic addition of a Grignard reagent to a Weinreb amide.31 A solid-phase method for synthesis of α-ketoamides has been developed.32 In this study, we have developed a convergent route to synthesize α-ketoamides by coupling a complex amine directly to an α-hydroxyorthothioester to form an α-hydroxyamide, which was then oxidized to an α-ketoamide with the Dess-Martin periodinane.33
We have reviewed Pin1 inhibitors, including synthetic inhibitors, and natural products.4,23 α-Ketoamides are an important class of inhibitor for PPIases (e.g. FK506); the co-crystal structure of FK506 with FKBP was the main evidence cited to support the “twisted amide” transition state for PPIases.5,34 But α-ketoamides have not yet been reported as Pin1 inhibitors. Our impetus for synthesizing these challenging phosphorylated α-ketoamides was to investigate the ability of these compounds to inhibit Pin1, the only PPIase that regulates the cell cycle.
α-Ketoamides 1a and 1b were designed based on the specificity of Pin1 for the pSer/pThr–Pro motif.18 An acetyl was chosen for the N-terminus, since co-crystal structures of Pin1-inhibitor complexes showed no electron density for N-terminal residues, and to improve water solubility over Fmoc derivatives.25,35,36 An aromatic naphthyl was introduced at the C-terminus based on substrate and inhibitor sequence specificities.18,36,37

Boc–Pro–OH and 2-(2-naphthyl)-ethylamine (NEA) were coupled with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide·HCl (EDC) to give Boc–Pro–NEA 2 (Scheme 1). Free amine 3 was prepared by TFA deprotection of 2, followed by neutralization with aqueous NaHCO3.
Scheme 1.
Synthesis of H–Pro–NEA 3.
Aldehyde 4 was obtained by LiAlH4 reduction of the Weinreb amide of protected Ser (Scheme 2).38 Lithio tris-methylthiomethane was added to aldehyde 4 to give orthothioester 5.39 The two diastereomers of orthothioester 5 were not separated at this stage, since the newly formed stereocenter would be eliminated in the subsequent oxidation of alcohol 7 to ketone 8. Orthothioester 5 was converted directly to α-hydroxyamide 6 by aminolysis.
Scheme 2.
Synthesis of inhibitors 1a and 1b.
The Boc group of 6 was removed with TFA, and the resulting amine was selectively acetylated with one equivalent of acetic anhydride in the presence of the free hydroxyl to give 7 (Scheme 2). Alcohol 7 was oxidized with the Dess-Martin reagent to form α-ketoamide 8.6,33 Although the Dess-Martin oxidation is known to produce the least epimerization alpha to electrophilic ketones,6,40,41 epimerization occurred either during oxidation or chromatography, but the diastereomers (1:1) were not separated at this stage. This epimerization occurs easily due to the strongly electron-withdrawing ketoamide group, and has been observed in several syntheses of α-ketoamides.15,29 Epimerization of α-ketoesters has been observed to occur in solution upon standing for one week.41 Both phospho-L-Thr and phospho-D-Thr containing inhibitors of Pin1 have been reported, and the D-Thr inhibitors were more potent.36,37 We wanted to test both diastereomers of 1 for inhibition, so we did not attempt to improve the stereochemical purity of α-ketoamide 8.
The benzyl on the side chain of serine was removed with BCl3 to give alcohol 9.42,43 Reverse-phase, semi-preparative HPLC purification gave a mixture of diastereomers of 9 in a 1:1 ratio as determined by 1H NMR (Supporting Information). The 86 ppm 13C NMR peak was assigned as the hydrated ketone carbon based on the literature, and the assignment below for 10a.1 The ketone carbonyl stretch did not appear in the IR at ca. 1720 cm−1, which also indicates hydration of the ketone.
Alcohol 9 was phosphorylated with dibenzyl N,N-diethylphosphoramidite, followed by oxidation with t-BuOOH to produce dibenzylphosphate 10.24,44 The diastereomers of 10 were isolated by reverse-phase semi-preparative HPLC. The ketone carbonyl for both diastereomers 10a and 10b appeared in the IR, but not in the 13C NMR. The 84 ppm peak in the 13C, and the 4.74 ppm peak in the 1H NMR were assigned by HMBC as the hydrated ketone (Supporting Information). The ketone carbonyl stretch appeared in the IR at 1723 cm−1, but much weaker than expected, indicating partial hydration.
Hydrogenolysis of each diastereomer of 10 under neutral conditions furnished two diastereomers of the final compound, 1a and 1b. Compounds 1a and 1b showed no ketone carbonyl in both the 13C and IR spectra. Since we found that both diastereomers were weak Pin1 inhibitors, vide infra, we chose not to determine the absolute stereochemistry of the inhibitors.
In our method, orthothioester 5 was directly reacted with the fully formed right half of the molecule, the amine H–Pro–NEA 3, as the nucleophile to produce amide 6 (Scheme 2). Orthothioester 5 was used as a carboxylic acid synthon instead of a nitrile to avoid the toxicity of NaCN or KCN. In addition, conditions for the hydrolysis of a nitrile are incompatible with amides.29
This synthesis of the target compound was convergent compared with previous linear syntheses of α-ketoamides via α-hydroxy acids. Previously, orthothioesters were either hydrolyzed to a carboxylic acid and coupled with an amine, or methanolyzed to a methyl ester.39,45,46 Methyl esters require the additional step of hydrolysis before coupling, while α-hydroxy acids are difficult to isolate and purify. Instead, the H–Pro–NEA amine was coupled in one step to the α-hydroxyorthothioester. We attempted ozonolysis of a cyano ylide to form the α-ketoamide functionality using Wasserman’s method.9 However, due to the instability of the α-ketoamide in subsequent Pro ester hydrolysis and coupling to NEA, we chose to use aminolysis of thioester 5 with amine 3 to form the complete skeleton prior to oxidation to the ketoamide.
The aminolysis was catalyzed by HgO and HgCl2, similar to hydrolysis of orthothioesters.39,45 Thus, the α-hydroxyamide 6 was formed without additional coupling reagents or steps. We propose that the key step in the reaction involves Hg(II)-catalyzed hydrolysis of the orthothioester to a methyl thioester intermediate 11 (Scheme 3).45,47 The THF used as the solvent was wet, which provided the water for the hydrolysis. Aminolysis with the amine nucleophile present in situ then gave amide 6 directly. Thus, hydrolysis and coupling were combined in a single step with 80% yield. Although the overall yield in this 12-step synthesis is not high (6% for the 9 linear steps), the aminolysis to form the key intermediate for α-ketoamides should be very useful in a variety of syntheses.
Scheme 3.
Proposed mechanism for hydroxyamide 6 formation.
The α-chymotrypsin protease-coupled assay, with succinyl–Ala–Glu–cis-Pro–Phe–p-nitroanilide (pNA) as the substrate, was used to measure inhibition of Pin1 by the two diastereomers of 1.24 The absorbance of pNA released from the PPIase trans product by chymotrypsin was recorded continuously at 390 nm by UV/Vis. The IC50 values of the two diastereomers were determined to be 100 ± 20 μM and 200 ± 20 μM.
Surprisingly, neither diastereomer was a potent inhibitor of Pin1. These inhibitors were less potent than a similarly substituted, ground-state analogue, Fmoc–pSer–Ψ[(Z)CH=C]–Pro–(2)-N-(3)-ethylaminoindole (IC50 = 28 μM).25 Since the α-ketoamide of FK506 acts as a transition state analogue to inhibit FKBPs,5 we expected more potent inhibition of Pin1 by at least one of the α-ketoamide stereoisomers. There are two proposed mechanisms for Pin1 catalysis: the twisted-amide mechanism,5,48,49 and the Cys-113 tetrahedral intermediate mechanism.50 The hemiketal of an α-ketoamide has been shown to act as a tetrahedral transition-state analogue for a serine protease.16 We anticipated that the ketoamide could act as a potent electrophile if the Cys-113 thiol of Pin1 were positioned for nucleophilic addition. The twisted amide mechanism is not supported by this poor inhibition either. Although a hydrated ketone would preclude either Cys-113 nucleophilic addition, or the orthogonal carbonyl conformation necessary to mimic the twisted amide transition state, as in FK506, the hydration is reversible. The ketone state should be accessible for binding to the enzyme if it were a favorable analogue of the transition state.
Although the two diastereomers of ketoamides were weak inhibitors of Pin1, we have provided a convergent method for synthesizing α-ketoamide peptidomimetics, which is a very useful class of enzyme inhibitors, especially for proteases. Many α-ketoamides have been developed as drugs, and our convergent method contributes to the available methods for their synthesis.
Supplementary Material
Acknowledgments
We thank the NIH for Grant No. R01 CA110940 for financial support.
Footnotes
Supporting Information Available: Experimental procedures, HPLC and spectroscopic data for compounds 1–10, and inhibition data for compound 1. This material is available free of charge via the Internet at http://pubs.acs.org.
References
- 1.Ocain TD, Rich DH. J Med Chem. 1992;35:451–456. doi: 10.1021/jm00081a005. [DOI] [PubMed] [Google Scholar]
- 2.Curtin M, Glaser K. Curr Med Chem. 2003;10:2373–2392. doi: 10.2174/0929867033456576. [DOI] [PubMed] [Google Scholar]
- 3.Wada CK, Frey RR, Ji Z, Curtin ML, Garland RB, Holms JH, Li J, Pease LJ, Guo J, Glaser KB, Marcotte PA, Richardson PL, Murphy SS, Bouska JJ, Tapang P, Magoc TJ, Albert DH, Davidsen SK, Michaelides MR. Bioorg Med Chem Lett. 2003;13:3331–3335. doi: 10.1016/s0960-894x(03)00685-1. [DOI] [PubMed] [Google Scholar]
- 4.Wang XJ, Etzkorn FA. Biopolymers. 2006;84:125–146. doi: 10.1002/bip.20240. [DOI] [PubMed] [Google Scholar]
- 5.Rosen MK, Standaert RF, Galat A, Nakatsuka M, Schreiber SL. Science. 1990;248:863–866. doi: 10.1126/science.1693013. [DOI] [PubMed] [Google Scholar]
- 6.Wipf P, Kim H. J Org Chem. 1993;58:5592–5594. [Google Scholar]
- 7.Maryanoff BE, Zhang HC, Greco MN, Glover KA, Kauffman JA, Andrade-Gordon P. Bioorg Med Chem. 1995;3:1025–1038. doi: 10.1016/0968-0896(95)00098-2. [DOI] [PubMed] [Google Scholar]
- 8.Ogilvie W, Bailey M, Poupart MA, Abraham A, Bhavsar A, Bonneau P, Bordeleau J, Bousquet Y, Chabot C, Duceppe JS, Fazal G, Goulet S, Grand-Maitre C, Guse I, Halmos T, Lavallée P, Leach M, Malenfant E, O’Meara J, Plante R, Plouffe C, Poirier M, Soucy F, Yoakim C, Déziel R. J Med Chem. 1997;40:4113–4135. doi: 10.1021/jm970104t. [DOI] [PubMed] [Google Scholar]
- 9.Wasserman HH, Petersen AK. J Org Chem. 1997:8972–8973. [Google Scholar]
- 10.Cacciola J, Fevig JM, Stouten PF, Alexander RS, Knabb RM, Wexler RR. Bioorg Med Chem Lett. 2000;10:1253–1256. doi: 10.1016/s0960-894x(00)00215-8. [DOI] [PubMed] [Google Scholar]
- 11.Li Z, Ortega-Vilain AC, Patil GS, Chu DL, Foreman JE, Eveleth DD, Powers JC. J Med Chem. 1996;39:4089–4098. doi: 10.1021/jm950541c. [DOI] [PubMed] [Google Scholar]
- 12.Choe Y, Brinen LS, Price MS, Engel JC, Lange M, Grisostomi C, Weston SG, Pallai PV, Cheng H, Hardy LW, Hartsough DS, McMakin M, Tilton RF, Baldino CM, Craik CS. Bioorg Med Chem. 2005;13:2141–2156. doi: 10.1016/j.bmc.2004.12.053. [DOI] [PubMed] [Google Scholar]
- 13.Shirasaki Y, Miyashita H, Yamaguchi M. Bioorg Med Chem. 2006;14:5691–5698. doi: 10.1016/j.bmc.2006.04.013. [DOI] [PubMed] [Google Scholar]
- 14.Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Jr, Wright LL. Bioorg Med Chem Lett. 2006;16:1735–1739. doi: 10.1016/j.bmcl.2005.11.101. [DOI] [PubMed] [Google Scholar]
- 15.Slee DH, Laslo KL, Elder JH, Ollmann IR, Gustchina A, Kervinen J, Zdanov A, Wlodawer A, Wong CH. J Am Chem Soc. 1995;117:11867–11878. [Google Scholar]
- 16.Maryanoff BE, Qiu X, Padmanabhan KP, Tulinsky A, Almond HR, Jr, Andrade-Gordon P, Greco MN, Kauffman JA, Nicolaou KC, Liu A, et al. Proc Natl Acad Sci U S A. 1993;90:8048–8052. doi: 10.1073/pnas.90.17.8048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lu KP, Hanes SD, Hunter T. Nature. 1996;380:544–547. doi: 10.1038/380544a0. [DOI] [PubMed] [Google Scholar]
- 18.Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, Cantley LC, Lu KP. Science. 1997;278:1957–1960. doi: 10.1126/science.278.5345.1957. [DOI] [PubMed] [Google Scholar]
- 19.Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP, Wang DG. Am J Pathol. 2004;164:1727–1737. doi: 10.1016/S0002-9440(10)63731-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ryo A, Liou YC, Lu KP, Wulf G. J Cell Sci. 2003;116:773–783. doi: 10.1242/jcs.00276. [DOI] [PubMed] [Google Scholar]
- 21.Finn G, Lu KP. Curr Cancer Drug Targets. 2008;8:223–229. doi: 10.2174/156800908784293622. [DOI] [PubMed] [Google Scholar]
- 22.Lu KP. Cancer Cell. 2003;4:175–180. doi: 10.1016/s1535-6108(03)00218-6. [DOI] [PubMed] [Google Scholar]
- 23.Xu GG, Etzkorn FA. Drug News Perspect. 2009;22:399–407. doi: 10.1358/dnp.2009.22.7.1381751. [DOI] [PubMed] [Google Scholar]
- 24.Wang XJ, Xu B, Mullins AB, Neiler FK, Etzkorn FA. J Am Chem Soc. 2004;126:15533–15542. doi: 10.1021/ja046396m. [DOI] [PubMed] [Google Scholar]
- 25.Zhao S, Etzkorn FA. Bioorg Med Chem Lett. 2007;17:6615–6618. doi: 10.1016/j.bmcl.2007.09.073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Wasserman HH, Ho WB. J Org Chem. 1994;59:4364–4366. [Google Scholar]
- 27.Ozawa F, Soyama H, Yanagihara H, Aoyama I, Takino H, Izawa K, Yamamoto T, Yamamoto A. J Am Chem Soc. 1985;107:3235–3245. [Google Scholar]
- 28.Chiou A, Verger R, Kokotos G. Lipids. 2001;36:535–542. doi: 10.1007/s11745-001-0754-0. [DOI] [PubMed] [Google Scholar]
- 29.Harbeson SL, Abelleira SM, Akiyama A, Barrett R, 3rd, Carroll RM, Straub JA, Tkacz JN, Wu C, Musso GF. J Med Chem. 1994;37:2918–2929. doi: 10.1021/jm00044a013. [DOI] [PubMed] [Google Scholar]
- 30.Han W, Jiang X, Hu Z, Wasserman ZR, Decicco CP. Bioorg Med Chem Lett. 2005;15:3487–3490. doi: 10.1016/j.bmcl.2005.06.003. [DOI] [PubMed] [Google Scholar]
- 31.Sibi MP, Marvin M, Sharma R. J Org Chem. 1995;60:5016–5023. [Google Scholar]
- 32.Papanikos A, Meldal M. J Comb Chem. 2004;6:181–195. doi: 10.1021/cc030107t. [DOI] [PubMed] [Google Scholar]
- 33.Dess DB, Martin JC. J Org Chem. 1983;48:4155–4156. [Google Scholar]
- 34.Fischer S, Michnick S, Karplus M. Biochemistry. 1993;32:13830–13837. doi: 10.1021/bi00213a011. [DOI] [PubMed] [Google Scholar]
- 35.Etzkorn FA, Noel JP, Zhang Y, Wang XJ. Understanding Biology Using Peptides. In: Blondelle SE, editor. Proc. 19th Am. Pept. Symp.; San Diego: Springer, Inc; 2006. pp. 759–762. [Google Scholar]
- 36.Zhang Y, Daum S, Wildemann D, Zhou XZ, Verdecia MA, Bowman ME, Lucke C, Hunter T, Lu KP, Fischer G, Noel JP. ACS Chem Biol. 2007;2:320–328. doi: 10.1021/cb7000044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Wildemann D, Erdmann F, Alvarez BH, Stoller G, Zhou XZ, Fanghanel J, Schutkowski M, Lu KP, Fischer G. J Med Chem. 2006;49:2147–2150. doi: 10.1021/jm060036n. [DOI] [PubMed] [Google Scholar]
- 38.Wang XJ, Hart SA, Xu B, Mason MD, Goodell JR, Etzkorn FA. J Org Chem. 2003;68:2343–2349. doi: 10.1021/jo026663b. [DOI] [PubMed] [Google Scholar]
- 39.Hu Z, Han W. Tetrahedron Lett. 2008:901–902. [Google Scholar]
- 40.Burkhart JP, Peet NP, Bey P. Tetrahedron Lett. 1988;29:3433–3436. [Google Scholar]
- 41.Patel DV, Rielly-Gauvin K, Ryono DE, Free CA, Smith SA, Petrillo EW., Jr J Med Chem. 1993;36:2431–2447. doi: 10.1021/jm00069a001. [DOI] [PubMed] [Google Scholar]
- 42.Williams DR, Brown DL, Benbow JW. J Am Chem Soc. 1989;111:1923–1925. [Google Scholar]
- 43.Xie J, Menand M, Valery JM. Carbohydrate Research. 2005;340:481–487. doi: 10.1016/j.carres.2004.12.001. [DOI] [PubMed] [Google Scholar]
- 44.de Bont HB, Liskamp RM, O’Brian CA, Erkelens C, Veeneman GH, van Boom JH. Int J Pept Protein Res. 1989;33:115–123. doi: 10.1111/j.1399-3011.1989.tb00196.x. [DOI] [PubMed] [Google Scholar]
- 45.Mamane V, Aubert E, Fort Y. J Org Chem. 2007;72:7294–7300. doi: 10.1021/jo071209z. [DOI] [PubMed] [Google Scholar]
- 46.Braukmüller S, Brückner R. Eur J Org Chem. 2006:2110–2118. [Google Scholar]
- 47.Orito K, Seki Y, Suginome H, Iwadare T. Bull Chem Soc Jpn. 1989;62:2013–2017. [Google Scholar]
- 48.Schroeder OE, Carper E, Wind JJ, Poutsma JL, Etzkorn FA, Poutsma JC. J Phys Chem A. 2006;110:6522–6530. doi: 10.1021/jp060642u. [DOI] [PubMed] [Google Scholar]
- 49.Wiederrecht G, Etzkorn FA. Perspect Drug Discov Des. 1994;2:57–84. [Google Scholar]
- 50.Ranganathan R, Lu KP, Hunter T, Noel JP. Cell. 1997;89:875–886. doi: 10.1016/s0092-8674(00)80273-1. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.



